GeneScience Pharmaceuticals
金赛药业
Executive Summary
GeneScience Pharmaceuticals is a Changchun-based biotech company with clear BIOSECURE status, making it a viable partner for US pharma deals. The company operates in China's competitive biotech landscape but lacks publicly available information on recent pipeline developments or deal activity. Limited transparency on corporate structure and leadership presents due diligence challenges despite regulatory clearance.
Structure: Corporate structure details are not publicly available, requiring deeper due diligence to understand ownership layers and potential VIE arrangements. As a Chinese biotech entity, standard structural complexities involving holding companies and variable interest entities should be expected during deal evaluation.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating lower regulatory risk for US partnerships
Key Exposures:
- •Standard China-based operations exposure
- •Potential future policy changes
Mitigation: Currently maintains clear BIOSECURE status with no active mitigation required
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals recorded in available data
Approach: Initial exploratory discussions recommended to assess pipeline assets and partnership interest, with emphasis on due diligence given limited public information
Red Flags
- ⚠Limited public disclosure of corporate information
- ⚠Absence of key personnel data
- ⚠No recorded recent deal activity or corporate events
- ⚠Unclear pipeline composition and development status
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.